Compare Abbott Laboratories (ABT) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Vanguard Short Term Corporate Bond ETF — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Vanguard Short Term Corporate Bond ETF trades at $78.6. The key difference: Abbott Laboratories pays a 2.63% dividend while Vanguard Short Term Corporate Bond ETF pays none, and Abbott Laboratories is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABT | VCSH | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Fixed Income |
52-Week High | $136.62 | $80.20 |
52-Week Low | $82.57 | $78.61 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
VCSH, the Vanguard Short-Term Corporate Bond ETF, trades at $78.85 with minimal daily movement (+0.08%). The technical picture is bearish with moving averages signaling selling pressure, while oscillators remain neutral. Recent news highlights VCSH's competitive advantages including a 4.3% yield and ultra-low 0.03% expense ratio compared to similar bond ETFs. The fund has attracted mixed institutional activity with some firms increasing positions while others reduced exposure.
VCSH offers investors exposure to short-term investment-grade corporate bonds with higher yields than Treasury alternatives, though with slightly more risk. The fund's low costs and monthly distributions make it attractive for income-focused portfolios, but investors face interest rate sensitivity and credit risk from its corporate bond holdings. Current technical weakness suggests potential for near-term price pressure despite the fund's solid fundamental positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
